ProLynx Announces Initiation of the Phase II Topology Clinical Trial of Its DNA-Damaging Agent PLX038 in Triple-Negative Breast Cancer at the Institut Curie

ProLynx, Inc. announced that the first patient was included in Topology by investigator Dr. Delphine Loirat, with a Phase II clinical trial investigating PLX038 for locally-advanced or metastatic TNBC.